Latest Breaking News On - Decheng capital global life science fund - Page 1 : comparemela.com

Cancer drug company CG Oncology Inc. priced its initial public offering above its estimated range and added three million shares to the deal in a bullish.

Arthur kuanCrossover fundi groupGoldman sachsCantor fitzgeraldCg oncology incKissei pharmaceutical coDecheng capital global life science fundMorgan stanleyLongitude venture partnersKissei pharmaceuticalForesite capitalRally bridgeNew nasdaqChief executiveAlly bridge groupArticle normal